Celldex Therapeutics, Inc. (CLDX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a research note released on Tuesday, August 1st, MarketBeat.com reports. The brokerage currently has a $10.00 target price on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on CLDX. Jefferies Group LLC reiterated a hold rating and issued a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a report on Thursday, May 11th. Zacks Investment Research upgraded Celldex Therapeutics from a hold rating to a buy rating and set a $3.50 price objective on the stock in a research report on Wednesday, May 31st. ValuEngine lowered Celldex Therapeutics from a sell rating to a strong sell rating in a research report on Saturday, June 3rd. Aegis reissued a buy rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Finally, BidaskClub downgraded Celldex Therapeutics from a sell rating to a strong sell rating in a research note on Monday, July 24th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $7.32.

Celldex Therapeutics (NASDAQ:CLDX) opened at 2.33 on Tuesday. The company’s market capitalization is $299.03 million. The firm has a 50-day moving average of $2.44 and a 200 day moving average of $2.97. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same quarter in the prior year, the company earned ($0.32) EPS. Celldex Therapeutics’s quarterly revenue was up 175.5% on a year-over-year basis. Analysts forecast that Celldex Therapeutics will post ($1.04) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Celldex Therapeutics, Inc. (CLDX) Stock Rating Reaffirmed by HC Wainwright” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/19/celldex-therapeutics-inc-cldx-receives-new-coverage-from-analysts-at-hc-wainwright-updated-updated.html.

Several institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC boosted its stake in Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 1,409 shares during the last quarter. Teachers Advisors LLC boosted its stake in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock valued at $593,000 after buying an additional 1,433 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 2,453 shares during the period. Nationwide Fund Advisors raised its position in Celldex Therapeutics by 3.5% in the second quarter. Nationwide Fund Advisors now owns 111,757 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 3,742 shares during the period. Finally, American International Group Inc. raised its position in Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 3,880 shares during the period. Institutional investors and hedge funds own 63.88% of the company’s stock.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

What are top analysts saying about Celldex Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celldex Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit